Mainstay Medical announces 2018 half-year financial results and update

Dublin, Ireland: 21 September 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on commercializing ReActiv8®, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling Chronic Low Back Pain, today announces the publication of its results for the Half Year ended 30 June 2018 and provides a company update.
  • ReActiv8-B study on track - full data readout expected towards the end of 2018;
  • Successfully completed financing of $ 37.5 million (€ 30 million) to fund completion of ReActiv8-B study and advance European commercialization;
  • Cash on hand of $ 29.7 million at 30 June 2018.

More info on Mainstay Medical's website.


Next > Nexstim Plc supports 10th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation

Previous > Nexstim Plc to present depression led strategy at Investor Conference Sijoittaja 2018 in Helsinki